| Zugriffe | |
|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 420 |
| Mai 2024 | Juni 2024 | Juli 2024 | August 2024 | September 2024 | Oktober 2024 | November 2024 | |
|---|---|---|---|---|---|---|---|
| CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 5 | 10 | 13 | 11 | 6 | 6 | 2 |
| Zugriffe | |
|---|---|
| diss_f.niehr.pdf | 215 |
